Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)

Sujoy Ghosh,1 Shailesh Trivedi,2 Debmalya Sanyal,3 KD Modi,4 Sandeep Kharb5 1Department of Endocrinology, The Institute of Post Graduate Medical Education and Research (IPGMER), Kolkata, West Bengal, 2Anand Hospital, Vadodara, Gujarat, 3Department of Endocrinology, KPC Medical College, Kolkata, West...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	teneligliptin DPP4 inhibitor Type 2 diabetes mellitus Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5c328f2ca75d4372b8d57ab03c1b0606
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5c328f2ca75d4372b8d57ab03c1b0606
record_format	dspace
spelling	oai:doaj.org-article:5c328f2ca75d4372b8d57ab03c1b06062021-12-02T01:51:34ZTeneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)1178-7007https://doaj.org/article/5c328f2ca75d4372b8d57ab03c1b06062016-11-01T00:00:00Zhttps://www.dovepress.com/teneligliptin-real-world-efficacy-assessment-of-type-2-diabetes-mellit-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Sujoy Ghosh,1 Shailesh Trivedi,2 Debmalya Sanyal,3 KD Modi,4 Sandeep Kharb5 1Department of Endocrinology, The Institute of Post Graduate Medical Education and Research (IPGMER), Kolkata, West Bengal, 2Anand Hospital, Vadodara, Gujarat, 3Department of Endocrinology, KPC Medical College, Kolkata, West Bengal, 4Dr Modi’s Clinic (DMC), Department of Endocrinology at Medwin Hospital, Hyderabad, Telangana, 5ASIAN Hospital, Faridabad, Haryana, India Background and aims: Teneligliptin was introduced in India in May 2015. It has gained popularity and is already widely prescribed in type 2 diabetes mellitus (T2DM). This “real life” data collection was conducted to assess the efficacy of teneligliptin in Indian T2DM patients. Methods: Predesigned structured proforma was used to collect information from the prescribing physicians regarding the efficacy of teneligliptin when prescribed as monotherapy as well as combination therapy with other antidiabetic drugs in T2DM patients. Information on the glycemic parameters at baseline prior to starting teneligliptin and at the end of 3 months therapy was collected. The efficacy was assessed by analyzing the mean change in 3-month values of glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG).Results: Data of 4305 patients was available for analysis. There was statistically significant improvement in mean HbA1c, FPG, and PPG with teneligliptin therapy. Means changes in HbA1c, FPG, and PPG were −1.37%±1.15%, 51.29±35.41 mg/dL, and 80.89±54.27 mg/dL, respectively. Subgroup analysis revealed that HbA1c (%) reduction with teneligliptin when used as monotherapy, add-on to metformin or add-on to metformin plus sulfonylureas combination, add-on to metformin plus alpha glucosidase inhibitor combination or add-on to insulin was 0.98±0.53, 1.07±0.83, 1.46±1.33, 1.43±0.80, and 1.55±1.05, respectively.Conclusion: Real-world data suggests that teneligliptin significantly improves glycemic control in Indian patients with T2DM when prescribed either as monotherapy or as an add-on to one or more other commonly prescribed antidiabetic drugs. Keywords: teneligliptin, DPP4 inhibitor, type 2 diabetes mellitusGhosh STrivedi SSanyal DModi KDKharb SDove Medical PressarticleteneligliptinDPP4 inhibitorType 2 diabetes mellitusSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 9, Pp 347-353 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	teneligliptin DPP4 inhibitor Type 2 diabetes mellitus Specialties of internal medicine RC581-951
spellingShingle	teneligliptin DPP4 inhibitor Type 2 diabetes mellitus Specialties of internal medicine RC581-951 Ghosh S Trivedi S Sanyal D Modi KD Kharb S Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
description	Sujoy Ghosh,1 Shailesh Trivedi,2 Debmalya Sanyal,3 KD Modi,4 Sandeep Kharb5 1Department of Endocrinology, The Institute of Post Graduate Medical Education and Research (IPGMER), Kolkata, West Bengal, 2Anand Hospital, Vadodara, Gujarat, 3Department of Endocrinology, KPC Medical College, Kolkata, West Bengal, 4Dr Modi’s Clinic (DMC), Department of Endocrinology at Medwin Hospital, Hyderabad, Telangana, 5ASIAN Hospital, Faridabad, Haryana, India Background and aims: Teneligliptin was introduced in India in May 2015. It has gained popularity and is already widely prescribed in type 2 diabetes mellitus (T2DM). This “real life” data collection was conducted to assess the efficacy of teneligliptin in Indian T2DM patients. Methods: Predesigned structured proforma was used to collect information from the prescribing physicians regarding the efficacy of teneligliptin when prescribed as monotherapy as well as combination therapy with other antidiabetic drugs in T2DM patients. Information on the glycemic parameters at baseline prior to starting teneligliptin and at the end of 3 months therapy was collected. The efficacy was assessed by analyzing the mean change in 3-month values of glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG).Results: Data of 4305 patients was available for analysis. There was statistically significant improvement in mean HbA1c, FPG, and PPG with teneligliptin therapy. Means changes in HbA1c, FPG, and PPG were −1.37%±1.15%, 51.29±35.41 mg/dL, and 80.89±54.27 mg/dL, respectively. Subgroup analysis revealed that HbA1c (%) reduction with teneligliptin when used as monotherapy, add-on to metformin or add-on to metformin plus sulfonylureas combination, add-on to metformin plus alpha glucosidase inhibitor combination or add-on to insulin was 0.98±0.53, 1.07±0.83, 1.46±1.33, 1.43±0.80, and 1.55±1.05, respectively.Conclusion: Real-world data suggests that teneligliptin significantly improves glycemic control in Indian patients with T2DM when prescribed either as monotherapy or as an add-on to one or more other commonly prescribed antidiabetic drugs. Keywords: teneligliptin, DPP4 inhibitor, type 2 diabetes mellitus
format	article
author	Ghosh S Trivedi S Sanyal D Modi KD Kharb S
author_facet	Ghosh S Trivedi S Sanyal D Modi KD Kharb S
author_sort	Ghosh S
title	Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
title_short	Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
title_full	Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
title_fullStr	Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
title_full_unstemmed	Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
title_sort	teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in india (treat-india study)
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/5c328f2ca75d4372b8d57ab03c1b0606
work_keys_str_mv	AT ghoshs teneligliptinrealworldefficacyassessmentoftype2diabetesmellituspatientsinindiatreatindiastudy AT trivedis teneligliptinrealworldefficacyassessmentoftype2diabetesmellituspatientsinindiatreatindiastudy AT sanyald teneligliptinrealworldefficacyassessmentoftype2diabetesmellituspatientsinindiatreatindiastudy AT modikd teneligliptinrealworldefficacyassessmentoftype2diabetesmellituspatientsinindiatreatindiastudy AT kharbs teneligliptinrealworldefficacyassessmentoftype2diabetesmellituspatientsinindiatreatindiastudy
_version_	1718402839286382592

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)

Ejemplares similares